The initial public offering (IPO) of Corona Remedies is set to list on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) on Monday, December 15, 2025. Ahead of its market debut, the grey market premium (GMP) for the IPO has been trending, indicating strong investor interest.
IPO Details and Subscription Status
Corona Remedies' IPO is a book-built issue of ₹655.68 crores. The issue is entirely an offer for sale of 0.62 crore shares. The IPO was open for subscription from December 8 to December 10, 2025. The finalization of allotment was completed on December 11, 2025. The IPO price band was fixed at ₹1,008 to ₹1,062 per share. Retail investors had to apply for a minimum of 14 shares, requiring an investment of ₹14,868 at the upper price band.
The IPO witnessed substantial investor interest, being oversubscribed by 137.04 times. Investors placed bids for 62,65,41,440 shares against the 45,71,882 shares on offer. The portion reserved for Qualified Institutional Buyers (QIBs) was subscribed 278.52 times, while Non-Institutional Investors (NIIs) subscribed 208.88 times their quota. Retail Individual Investors (RIIs) subscribed 28.73 times the allotted portion.
Grey Market Premium (GMP)
As of December 12, 2025, the grey market premium (GMP) for Corona Remedies IPO was ₹305. Some sources indicated a GMP between ₹300 and ₹310. This suggests that the shares are expected to list at around ₹1,367 to ₹1,372 per share. This translates to a potential listing gain of approximately 28% to 29% over the issue price of ₹1,062.
It's important to note that the GMP is an unofficial, speculative indicator and doesn't guarantee listing gains. However, it reflects market sentiment and investor expectations.
Refunds and Demat Account Credit
Refunds for non-allottees were initiated on December 12, 2025. Shares were also credited to the Demat accounts of successful bidders on the same day.
Company Overview
Corona Remedies is a pharmaceutical company headquartered in India, involved in developing, manufacturing, and marketing a wide range of pharmaceutical formulations. The company focuses on therapeutic areas such as women's healthcare, cardio-diabetology, pain management, and urology. As of December 2024, Corona Remedies had a diversified portfolio of 67 brands. The company has two manufacturing facilities in Gujarat and Himachal Pradesh. Corona Remedies is the second fastest-growing company among the top 30 in the Indian Pharmaceutical Market (IPM) based on domestic sales as of December 2024. Between fiscal years 2023 and 2025, the company's revenue grew at a compounded annual growth rate (CAGR) of 18%.
